Export

EN
FR
Amphotericin B
Essential medicine status
Section:
6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.2. Antileishmaniasis medicines
ATC codes: J02AA01
EMLc
Indication
Visceral leishmaniasis ICD11 code: 1F54.0
INN
Amphotericin B
Medicine type
Chemical agent
List type
Core (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 50 mg in vial powder for injection (liposomal complex) ; 50 mg in vial powder for injection (as sodium deoxycholate)
EML status history
First added in 1995 (TRS 867)
Changed in 2007 (TRS 950)
Changed in 2009 (TRS 958)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Wikipedia
Amphotericin B
DrugBank
Amphotericin b
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for amphotericin B on the EML and EMLc be amended to list the liposomal and deoxycholate formulations separately, and the inclusion of a note to indicate that liposomal amphotericin B is the preferred formulation because of its better safety profile.